Darling Ingredients Announces Publication of Peer-Reviewed Collagen Peptides Study and its Impact on Post-Meal Blood Glucose Spikes

Follow Drugslib on

IRVING, Texas, Oct. 21, 2024. Darling Ingredients Inc. today announced the publication of preclinical and clinical studies1 in the Wiley Journal of Food Science and Nutrition, focusing on the impact of a specific collagen peptide composition on post-meal blood glucose spikes.

Developed by Darling Ingredients' premier collagen and gelatin brand, Rousselot, the Nextida library features a groundbreaking collection of specific collagen peptide compositions with new targeted health benefits. The first product in this range, Nextida GC, has shown significant potential in mitigating post-meal glucose spikes in healthy individuals.

This potential was confirmed in preclinical studies on mice and a proof-of-concept clinical study involving healthy individuals, including those with normoglycemia as well as prediabetes. In this first clinical trial, participants who consumed 5- or 10-gram doses of Nextida GC 30 minutes before a meal experienced a 42% reduction in blood glucose spike on average after the meal.2

"We are proud of this publication, which supports our discoveries, underscores the robustness of our scientific research, and highlights the potential of Nextida GC," said Randall C. Stuewe, Chairman and CEO, Darling Ingredients. "This product represents a significant breakthrough in the field of collagen peptides and offers a promising new option for individuals seeking safe and natural supplements to enhance their well-being."

As consumer demand for natural and effective health solutions continues to grow, Darling Ingredients is committed to leading the way in the development of new collagen-based products that offer health benefits extending beyond traditional ones.

About Darling IngredientsA pioneer in circularity, Darling Ingredients Inc. takes material from the animal agriculture and food industries, and transforms them into valuable ingredients that nourish people, feed animals and crops, and fuel the world with renewable energy. The company operates over 260 facilities in more than 15 countries and processes about 15% of the world's animal agricultural by-products, produces about 30% of the world's collagen (both gelatin and hydrolyzed collagen), and is one of the largest producers of renewable energy.

Cautionary Statements Regarding Forward-Looking InformationThis release may contain "forward-looking statements," which include information concerning the Company's plans, objectives, goals and strategies and other information that is not historical information. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied by the forward-looking statements contained in this release. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

References

1 - Grasset, E., et al., A Specific Collagen Hydrolysate Improves Postprandial Glucose Tolerance in Normoglycemic and Prediabetic Mice and in a First Proof of Concept Study in 16 Healthy, Normoglycemic, and Prediabetic Humans. Wiley Journal of Food Science and Nutrition, Article ID: FSN34538, Article DOI: 10.1002/fsn3.4538, Inertanal Article ID: 100074727.2 - Reduced post-meal glucose spike by 43% (5-gram dose) and 40% (10-gram dose).

SOURCE Darling Ingredients Inc.

Posted : 2024-10-22 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords